Infinite Epigenetics

Based in the US, Infinite Epigenetics provides advanced diagnostic testing focused on chronic diseases through innovative epigenetic technologies, offering critical insights for healthcare providers and research institutions. Infinite Epigenetics specializes in diagnostic testing that employs epigenetic technology to detect chronic diseases early. Founded in 2025 in Lexington, US, the company has focused on building a strong foundation in epigenetic research. The company was founded by individuals who have significant expertise in the field, although specific details about their previous ventures are not available.

Infinite Epigenetics specializes in advanced diagnostic testing focused on chronic diseases through innovative epigenetic technology. The company’s core product offerings include a blood-based test that analyzes DNA methylation to detect and predict the risk of diseases such as Type 2 Diabetes, Coronary Artery Disease, and Chronic Kidney Disease long before clinical symptoms arise. By utilizing proprietary algorithms and artificial intelligence, the tests provide comprehensive insights into an individual's health, leveraging data from over 100,000 epigenetic samples. The company's solution is aimed at healthcare providers, pharmaceutical companies, and research institutions, with a focus on global markets, particularly in North America and Europe, where chronic diseases significantly impact public health.

Infinite Epigenetics generates revenue through a subscription-based model, offering diagnostic tests to healthcare providers and institutions involved in disease management and prevention. Each transaction typically involves clients ordering tests for their patient populations, where results are delivered via a digital platform, allowing for timely analysis and integration into patient care plans. Pricing structures are designed to accommodate both individual tests and bulk orders for institutions, facilitating widespread accessibility to their epigenetic insights. The company also engages in partnerships with pharmaceutical firms for research and development of personalized medicine solutions, further enhancing its revenue streams through collaborative agreements and studies.

Infinite Epigenetics plans to introduce new products aimed at expanding its diagnostic capabilities, targeting additional chronic diseases with anticipated launches expected in the next 24 months. The company is looking to expand its reach into European markets, aiming for a significant presence by 2026. Recent funding will be utilized to support these initiatives, further enhancing research capabilities and developing strategic partnerships in the healthcare sector for better integration of its technologies.